A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial
Autor: | Nick Maisey, Elisa Fontana, Nicola Valeri, Andrea Lampis, Elizabeth C Smyth, S.J. Lin, Matteo Fassan, Andrew Davies, Jesper Lagergren, William H. Allum, G. Nyamundanda, Jens C. Hahne, Anguraj Sadanandam, C. Ragulan, Ruth E Langley, J Zylstra, Matthew Nankivell, James A. Gossage, I.B. Tan, David Cunningham, Patrick Tan, A C Wotherspoon, Mark L. Green |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Oncology Male Esophageal Neoplasms medicine.medical_treatment Kaplan-Meier Estimate 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols Medicine Prospective Studies Prospective cohort study Neoadjuvant therapy Oesophageal cancer Hazard ratio Stomach Statistical regression analysis Hematology Middle Aged Prognosis Gastric cancer MAGIC Trial Perioperative chemotherapy Prognostic biomarker Chemotherapy regimen Neoadjuvant Therapy Treatment Outcome Chemotherapy Adjuvant 030220 oncology & carcinogenesis Female Risk assessment Adult Prognostic variable medicine.medical_specialty Risk Assessment 03 medical and health sciences Stomach surgery Esophagus Gastrectomy Stomach Neoplasms Internal medicine Biomarkers Tumor Humans Aged business.industry Gene Expression Profiling Gene signature Esophagectomy 030104 developmental biology Neoplasm Recurrence Local business Transcriptome |
Popis: | Background Following neoadjuvant chemotherapy for operable gastroesophageal cancer, lymph node metastasis is the only validated prognostic variable; however, within lymph node groups there is still heterogeneity with risk of relapse. We hypothesized that gene profiles from neoadjuvant chemotherapy treated resection specimens from gastroesophageal cancer patients can be used to define prognostic risk groups to identify patients at risk for relapse. Patients and methods The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial (n = 202 with high quality RNA) samples treated with perioperative chemotherapy were profiled for a custom gastric cancer gene panel using the NanoString platform. Genes associated with overall survival (OS) were identified using penalized and standard Cox regression, followed by generation of risk scores and development of a NanoString biomarker assay to stratify patients into risk groups associated with OS. An independent dataset served as a validation cohort. Results Regression and clustering analysis of MAGIC patients defined a seven-Gene Signature and two risk groups with different OS [hazard ratio (HR) 5.1; P |
Databáze: | OpenAIRE |
Externí odkaz: |